Samsara Bio Capital, LLC Iveric Bio, Inc. Transaction History

Samsara Bio Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $9.94 Million - $15 Million	-378,684 Reduced 55.13%	308,151 $12.1 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $12.8 Million - $16.9 Million	686,835 New	686,835 $16.7 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $1.9 Million - $3.76 Million	-202,010 Reduced 20.0%	808,041 $14.5 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $2.3 Million - $4.77 Million	-252,500 Reduced 20.0%	1,010,051 $9.72 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $2.77 Million - $3.76 Million	-200,283 Reduced 13.69%	1,262,551 $21.1 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $4.68 Million - $11.6 Million	-662,537 Reduced 31.17%	1,462,834 $23.8 Million
Q2 2021 Aug 17, 2021	SELL	$5.69 - $7.17 $1.41 Million - $1.77 Million	-247,105 Reduced 10.42%	2,125,371 $13.4 Million
Q4 2020 Feb 17, 2021	SELL	$5.65 - $7.66 $5.64 Million - $7.64 Million	-998,002 Reduced 29.61%	2,372,476 $16.4 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $7.67 Million - $16.6 Million	2,507,926 Added 290.76%	3,370,478 $17.2 Million
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $460,022 - $1.37 Million	162,552 Added 23.22%	862,552 $2.97 Million
Q4 2019 Feb 18, 2020	BUY	$0.93 - $8.58 $651,000 - $6.01 Million	700,000 New	700,000 $6.01 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.